|
It was reported that the procedure was to treat an occlusion in the distal posterior tibial artery.The 3.75x28mm esprit btk scaffold was implanted; however, a flow-limiting dissection was noted, resulting in worsening of the stenosis severity.Therefore, post dilatation was performed which improved the dissection.No additional information was provided.
|
|
The device was not returned for analysis.Production record and corrective and preventative actions (capa) reviews were performed and revealed no indication of a product quality issue.Additionally, a query of the complaint handling database for the reported lot revealed there is no indication of a lot specific issue.A conclusive cause for the reported patient effect(s), and the relationship to the product, if any, cannot be determined; however, the subsequent treatment appears to be related to the operational context of the procedure.The reported patient effect(s) of occlusion and dissection are listed in the esprit btk everolimus eluting resorbable scaffold systems instructions for use as a known patient effect(s) of scaffolding procedures.There is no indication of a product quality issue with respect to manufacture, design or labeling¿ therefore, no product-related corrective action will be implemented in this case.C3: 1 per year was entered; however, the frequency is 1 dose per implant.
|